eMC Medicine Guides  
The electronic Medicines Compendium (eMC) contains information about UK licensed medicines.
go to eMC homepage
Search for:  
  Advanced Search

Chugai Pharma UK Limited
Mulliner House, Flanders Road, Turnham Green, London, W4 1NN
Telephone: +44 (0)208 987 5600
Fax: +44 (0)208 987 5660

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?
Summary of Product Characteristics last updated on the eMC: 22/01/2008
SPC Antepsin Tablets 1g

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 22/01/2008 and displayed until Current
Reasons for adding or updating:
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   11/2007
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company
Amendments have been made to harmonise UK and Irish SmPC's:
 
Section 4.2: Inclusion of maximum dose and removal of 'prophylaxis of gastrointestinal haemorrhage from stress ulceration'

Section 4.4: Inclusion of Bezoars warning statement
 
Section 4.5: Inclusion of warning statement on the concomitant use of Antepsin Tablets and enteral feeds by nasogastric tube
Updated on 05/12/2006 and displayed until 22/01/2008
Reasons for adding or updating:
  • Change to section 1 -Name of the Medicinal product
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 3 - Pharmaceutical form
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable Effects
  • Change to section 6.1 - List of Excipients
Date of revision of text on the SPC:   11/2006
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company
 

Sections 1 to 3: Updated in line with EU SmPC Guideline

Section 4.5: Theophylline, thyroxine and quinidine added. Concomitant administration of Antepsin may reduce the bioavailability of these drugs.

Section 4.7: Driving warning updated as drowsiness and dizziness are listed as undesirable effects

Section 4.8: 'Shortness of breath' added in line with patient information leaflet

Section 6.1: Updated excipients Calcium carboxymethyl cellulose to INN calcium carmellose
Updated on 19/02/2004 and displayed until 05/12/2006
Reasons for adding or updating:
  • Change to section 6. 5 - Nature and Contents of Container
  • Change to section 10 (date of (partial) revision of the text
Updated on 03/06/2003 and displayed until 19/02/2004
Reasons for adding or updating:
  • Change to section 6.1 - List of Excipients
  • Change to section 6. 5 - Nature and Contents of Container
  • Change to section 10 (date of (partial) revision of the text
Updated on 28/08/2001 and displayed until 03/06/2003
Reasons for adding or updating:
  • No reasons supplied
Updated on 02/11/2000 and displayed until 28/08/2001
Reasons for adding or updating:
  • No reasons supplied

Active Ingredients/Generics

 
  sucralfate